Edarbi
(Azilsartan medoxomil)Phase 3Small molecule
TakedaAzilsartan medoxomil is used to treat high blood pressure. It helps relax blood vessels so blood can flow more easily, reducing the strain on your heart.[1] Edarbi is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
Edarbi is one of 146 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.
5
Indications
26
Total Trials
1
Active Trials
145
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Edarbi
TakedaPhase 3
Benicar
NovartisPreclinical
Apresoline
NovartisPreclinical
Zebeta
TevaPreclinical
Edarbi
TakedaPreclinical
Aceon
Institut de Recherches Internationales ServierPreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Essential Hypertension12 trials
Show 9 more trials
Hypertension10 trials
Show 7 more trials
Kidney Disease1 trial
High Blood Pressure1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Azilsartan medoxomil. EMBL-EBI & Wellcome Sanger Institute.
- [4]